节律性化疗在晚期肝细胞肝癌中的应用进展
发布时间：2018-11-26 17:07
【摘要】：原发性肝癌是我国常见的消化系统恶性肿瘤,其中以肝细胞肝癌(hepatocellular carcinoma,HCC)为最多见。多数HCC患者确诊时已为晚期,丧失了手术和局部治疗的机会,系统治疗被认为是晚期HCC的主要治疗方式。传统细胞毒类药物化疗对晚期HCC效果不明显,分子靶向药物索拉非尼虽有生存获益,但客观有效率仅为2%~3%,且价格昂贵。节律性化疗由于靶向肿瘤新生血管,在晚期转移性癌症中的治疗作用越来越受到关注。本文拟对节律性化疗在晚期HCC中的治疗进展做一简要综述。
[Abstract]:Primary liver cancer (HCC) is a common malignant tumor of digestive system in China, of which hepatocellular carcinoma (hepatocellular carcinoma,HCC) is the most common. The majority of HCC patients have been diagnosed as late, lost the opportunity of surgery and local treatment, systemic therapy is considered as the main treatment of late HCC. The effect of traditional cytotoxic drugs chemotherapy on advanced HCC is not obvious. Although the molecular targeted drug Solafenib has the benefit of survival, the objective effective rate is only 2%, and the price is high. Rhythmic chemotherapy has attracted more and more attention in the treatment of advanced metastatic cancer due to its targeting tumor neovascularization. This article reviews the progress of rhythmic chemotherapy in the treatment of advanced HCC.
【作者单位】： 上海东方肝胆外科医院;
【分类号】：R735.7
[Abstract]:Primary liver cancer (HCC) is a common malignant tumor of digestive system in China, of which hepatocellular carcinoma (hepatocellular carcinoma,HCC) is the most common. The majority of HCC patients have been diagnosed as late, lost the opportunity of surgery and local treatment, systemic therapy is considered as the main treatment of late HCC. The effect of traditional cytotoxic drugs chemotherapy on advanced HCC is not obvious. Although the molecular targeted drug Solafenib has the benefit of survival, the objective effective rate is only 2%, and the price is high. Rhythmic chemotherapy has attracted more and more attention in the treatment of advanced metastatic cancer due to its targeting tumor neovascularization. This article reviews the progress of rhythmic chemotherapy in the treatment of advanced HCC.
【作者单位】： 上海东方肝胆外科医院;
【分类号】：R735.7
【相似文献】
相关期刊论文 前10条
1 王英,李开宗,李玉松;肝细胞肝癌中p15,p16基因表达的关系[J];第四军医大学学报;2000年06期
2 朱立新,耿小平;肝细胞肝癌术后复发的危险因素、预防及治疗[J];肝胆外科杂志;2000年06期
3 季伟,王慧芬;乙型肝炎病毒感染合并肝细胞肝癌153例临床分析[J];中华肝脏病杂志;2001年06期
4 陈孝平;张志伟;杨甲梅;沈锋;;肝细胞肝癌外科治疗方法的选择[J];中华普通外科学文献(电子版);2008年06期
5 董硕;谢广茹;吴雄志;;男性肝细胞肝癌术后预后因素分析[J];中国肿瘤临床;2008年08期
6 陈孝平;张志伟;杨甲梅;沈锋;;肝细胞肝癌外科治疗方法的选择[J];中华普通外科学文献(电子版);2009年02期
7 郭洪生;杜智;高英堂;薛春祥;张勤;朱争艳;王伟丽;;磷脂酰肌醇蛋白聚糖3在肝细胞肝癌中的表达及意义[J];中国肿瘤临床;2009年08期
8 陈孝平;张志伟;杨甲梅;沈锋;;肝细胞肝癌外科治疗方法的选择[J];中华普通外科学文献(电子版);2010年01期
9 徐霁;;多齿针大剂量乙醇消融治疗直径5.0cm以内的肝细胞肝癌[J];国际医学放射学杂志;2010年01期
10 张国强;杨定华;李相z，
本文编号：2359136
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2359136.html
